TMO Stock Set to Gain From the Launch of New Narcotic Analyzers
Thermo Fisher launches new TruNarc analyzers to help law enforcement quickly detect 1,200+ substances, boosting field safety and drug interdiction efforts.
Thermo Fisher: Tariffs Hit, Valuation Compensates
The macro environment has clearly deteriorated, with tariffs and U.S. policy weighing on short-term earnings. Management revised EPS down ~$1, but revenue guidance held as pricing and FX helped off...
Thermo Fisher's Q1 Earnings Top Estimates, Revenues Beat, Stock Up
TMO continues to advance its growth strategy and trusted partner status with customers in the first quarter of 2025.
Thermo Fisher Scientific Inc. (TMO) Q1 2025 Earnings Call Transcript
Thermo Fisher Scientific Inc. (NYSE:TMO ) Q1 2025 Earnings Conference Call April 23, 2025 8:30 AM ET Company Participants Rafael Tejada - Vice President, Investor Relations Marc Casper - Chairman, ...
Stay Ahead of the Game With Thermo Fisher (TMO) Q1 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of Thermo Fisher (TMO) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates ...
TMO Stock Set to Gain From The Launch of New Spatial Imaging System
Thermo Fisher's Invitrogen EVOS S1000 Spatial Imaging System addresses the limitations of current fluorescent microscopy technologies.
Thermo Fisher Scientific: Finally Ready For A Breakout? (Upgrade)
Thermo Fisher returned to growth in 4Q 2024 across all segments, and 2025 EPS growth is projected at 6.6% supported by margin expansion. Despite rich industry valuations, Thermo trades at a discoun...
Thermo Fisher Scientific (TMO) Q4 Earnings and Revenues Top Estimates
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $6.10 per share, beating the Zacks Consensus Estimate of $5.93 per share. This compares to earnings of $5.67 per share a year ago.
Robust Analytical Instruments Segment Likely to Aid TMO's Q4 Earnings
Strength in Analytical Instruments and Specialty Diagnostics segments is likely to have driven Thermo Fisher's fourth-quarter 2024 performance.
Biologicals Is The Future In Thermo Fisher: Buy Rating
Thermo Fisher Scientific is poised for growth in 2025, driven by aging demographics, higher healthcare spending, and demand for innovative biological medicines. TMO's diverse revenue streams, inclu...
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bioproduction Prospects to Drive TMO Shares Despite Macroeconomic Woes
TMO's recent strategic acquisitions, including the $3.1-billion acquisition of Olink Holdings, are likely to drive future growth.
Thermo Fisher: The Cycle Has Already Turned Around
Thermo Fisher's stock is now a "buy" due to signs of recovery, including positive sales growth and stabilized margins, despite recent bearish trends. The company's post-pandemic challenges are easi...
TMO Institutional & Insider Stock Sell-Offs Upset Market: How to Play
Investors are also concerned about Thermo Fisher's continuous decline in testing revenues due to the decline in COVID testing-related demand.
Should You Continue to Hold TMO Stock in Your Portfolio?
Investors continue to be optimistic about Thermo Fisher due to its strategic acquisitions and string of product launches.
Related Companies